Angle Plc Surrey Stock Price, News & Analysis

ANGLE plc (OTCQX:ANPCY), a leading liquid biopsy company specializing in circulating tumour cell (CTC) solutions, has announced the appointment of Cavendish Capital Markets Limited as its new Nominated Adviser and Sole Broker, effective immediately.

The company, which focuses on innovative solutions for research, drug development, and clinical oncology, made this change in its advisory relationships to support its ongoing business operations. The appointment demonstrates ANGLE's commitment to maintaining strong market relationships and corporate governance standards.

ANGLE plc (OTCQX:ANPCY), a pioneering liquid biopsy company specializing in circulating tumour cell (CTC) diagnostic solutions, has scheduled the release of its interim results for H1 2025 on September 9, 2025.

The company will host a virtual analyst meeting at 11:00 am BST due to planned tube strikes. The event will include a live webcast accessible through ANGLE's Investor Centre page, with Q&A participation limited to analysts. A recording will be made available on the company's website after the meeting.

ANGLE plc (OTCQX:ANPCY) has announced a strategic collaboration with Myriad Genetics (NASDAQ:MYGN) to evaluate the feasibility of using Parsortix-derived circulating tumor cell (CTC) DNA with Myriad's existing tissue-based diagnostic tests.

Under the agreement, ANGLE's R&D team will process cancer patient blood samples using their Parsortix® system to capture intact cancer cells for molecular analysis. The study will compare CTC-DNA results with matched patient tissue samples using Myriad's current tissue-based assay. The specific terms of the agreement remain confidential between the parties.

ANGLE plc (OTCQX:ANPCY), a leading liquid biopsy company, announced a significant publication in Nature Genetics by ETH Zurich researchers utilizing the company's Parsortix® system. The study investigated genetic diversity in circulating tumor cell (CTC) clusters in breast cancer.

The research revealed that CTC clusters are up to 100 times more metastatic than individual CTCs, with metastatic spread responsible for over 90% of cancer-related deaths. The study found higher prevalence of CTC clusters in high-complexity tumors, with some mutations being exclusive to specific cells within CTC clusters that could be missed by traditional tissue biopsies.

The findings position CTC clusters as crucial targets for stopping cancer spread, highlighting Parsortix's capability to overcome spatial and temporal limitations of conventional tissue biopsy methods.

ANGLE plc (OTCQX:ANPCY), a world-leading liquid biopsy company, has announced that all resolutions presented at its 2025 Annual General Meeting were successfully passed. The company will make detailed voting results available on its corporate website.

ANGLE plc presented new data at EACR 2025 showcasing their DNA dual analysis workflow for comprehensive liquid biopsy profiling in lung cancer patients. The study, conducted using ANGLE's Parsortix system and Illumina's NextSeq2000 platform, analyzed both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) using a 79-gene lung cancer panel. The research demonstrated high sensitivity in detecting clinically relevant mutations in contrived samples. In the analysis of 27 lung cancer patients, the study revealed significant differences between CTC-DNA and ctDNA, with 53% of mutations found only in CTCs, 36% only in ctDNA, and 11% in both. The findings highlighted ANGLE's unique capability to identify druggable targets through CTC-DNA analysis, including mutations in genes like CHEK2, ESR1, NTRK1, and RET, which correspond to various targeted therapies from major pharmaceutical companies.

ANGLE plc presented new data at EACR 2025 showcasing their innovative CTC-based assay for Androgen Receptor (AR) expression profiling in prostate cancer. The company developed a novel approach using the Parsortix system and AR immunofluorescence assay, demonstrating high sensitivity in monitoring AR expression levels. Testing on spiked blood samples showed significant AR expression reduction from 80% to 20% with increasing AR-drug concentrations. In clinical validation with 20 mCRPC patients, 50% showed CTC-positive results, all with AR-positive CTCs. The assay addresses a crucial need in the projected $9.8B AR inhibitor market by 2032, offering real-time monitoring capabilities for drug response and resistance in prostate cancer trials. The technology is now available as part of ANGLE's assay menu for pharmaceutical customers.

ANGLE plc has announced three significant peer-reviewed publications highlighting novel discoveries in cancer biology using their Parsortix system. The first study from University Medical Center Hamburg-Eppendorf revealed substantial release of cancer cells during prostate cancer surgery. The second study by Trinity College Dublin showed higher yields of circulating tumor cells (CTCs) in local tumor veins during ovarian cancer surgery. The third study by Cleveland Clinic researchers investigated biomechanical adaptations in breast cancer cells, finding that mechanical conditioning scores increase through the metastatic cascade. These discoveries demonstrate Parsortix's crucial role in advancing cancer research and potential therapeutic developments.

ANGLE plc (OTCQX:ANPCY), a liquid biopsy company specializing in circulating tumour cell (CTC) solutions, has announced the distribution of its 2024 Annual Report and Financial Statements along with the AGM notice to shareholders. The Annual General Meeting is scheduled for June 30, 2025, at 2:00 pm at the Surrey Technology Centre in Guildford. The company will provide shareholders with a business update following the formal proceedings. The documents are also available on the company's website for review.